Advisory Panel Meeting Menu Includes Self-Selection Risk/Benefit Evaluation

FDA's Nonprescription Drugs Advisory Committee will tackle issues such as weighing the risks of self-selection failures against the benefit of successes when the panel convenes Sept. 25 to discuss OTC drug consumer behavior trials